ProteinQure is the best computational platform for peptide drug discovery. ProteinQure partners with pharma to deliver experimentally validated novel chemical matter (ProteinQure doesn’t sell software). The company focuses on designing novel small proteins optimized for binding, specificity, developability and serum stability using non-canonical amino acids. ProteinQure  has designed peptides that would be impossible for other tools such as Rosetta or Alphafold2. ProteinQure’s validation includes multiple success in-vivo and unprecedented in-vitro characteristics. These peptides can also be used as therapeutics or delivery agents for modalities such as siRNA or cytotoxic agents. ProteinQure has many commercial partnerships with pharma including its first with AstraZeneca and two additional top 25 pharma companies. It is currently looking for more partners to access its platform and proprietary peptides to help with early stage hit id and lead optimization. ProteinQure also has a small internal portfolio of homing peptides for delivering therapeutic payloads to specific tissues (including a tumour specific antigen and the CNS).

ProteinQure logo



Event details

Date: November 6 - 8, 2023

Event contact

Patrick Barry
Area Director
Europe: Automotive and Life Sciences


21 in total